University of Lausanne at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
University of Lausanne brings 2 presentations to ESGCT 2026 in Hamburg. Its work runs from RNA repair in inherited retinal disease to engineered T cell therapy. One line recruits ADAR enzymes to correct retinal disease mutations at the RNA level, another packs next-generation T cell designs into single all-in-one lentiviral vectors.
| Organization | ESGCT 2026 Attendance |
|---|---|
University of Lausanne Lausanne, Switzerland | |
Public university in Lausanne, Switzerland. | Poster Thu Oct 29 2:00pm–4:00pm RetinADAR: Targeted ADAR recruitment to correct IRD mutations at the RNA level Talk Thu Oct 29 4:00pm–6:00pm Designing and Integrating Next-Generation T Cell Strategies With Modular All-in-One Lentiviral Vectors Vectors and delivery (AAV, lentiviral, LNP)Cell therapies and CAR-T |
Instantly find 20 buyers from University of Lausanne
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction